CTLA4 and Mental deterioration: Furthermore, immune-related hypophysitis, observed in up to 18% of patients treated with the CTLA-4 inhibitor ipilimumab [34], may cause pituitary dysfunction and hormonal imbalance, which can manifest clinically as fatigue, mood alterations, and cognitive decline [35].